212 related articles for article (PubMed ID: 24129131)
1. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials.
Kavanaugh A; Smolen JS
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S19-21. PubMed ID: 24129131
[TBL] [Abstract][Full Text] [Related]
2. The BeSt way of withdrawing biologic agents.
Allaart CF; Lems WF; Huizinga TW
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
[TBL] [Abstract][Full Text] [Related]
3. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
Caporali R; Scirè CA; Todoerti M; Montecucco C
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S9-13. PubMed ID: 24129129
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of biologics in patients with rheumatoid arthritis.
Tanaka Y; Hirata S; Saleem B; Emery P
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S22-7. PubMed ID: 24129132
[TBL] [Abstract][Full Text] [Related]
5. Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.
Yoshida K; Radner H; Kavanaugh A; Sung YK; Bae SC; Kishimoto M; Matsui K; Okada M; Tohma S; Weinblatt ME; Solomon DH
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S28-32. PubMed ID: 24129133
[TBL] [Abstract][Full Text] [Related]
6. Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?
Cannella AC; O'Dell JR
Curr Opin Rheumatol; 2003 May; 15(3):185-92. PubMed ID: 12707569
[TBL] [Abstract][Full Text] [Related]
7. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
Chen DY; Lau CS; Elzorkany B; Hsu PN; Praprotnik S; Vasilescu R; Marshall L; Llamado L
Int J Rheum Dis; 2018 Feb; 21(2):362-372. PubMed ID: 29205904
[TBL] [Abstract][Full Text] [Related]
8. Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis?
Lubrano E; Soriano E; FitzGerald O
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S54-8. PubMed ID: 24129139
[TBL] [Abstract][Full Text] [Related]
9. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation.
Iwamoto T; Ikeda K; Hosokawa J; Yamagata M; Tanaka S; Norimoto A; Sanayama Y; Nakagomi D; Takahashi K; Hirose K; Sugiyama T; Sueishi M; Nakajima H
Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1576-81. PubMed ID: 24515410
[TBL] [Abstract][Full Text] [Related]
10. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
[TBL] [Abstract][Full Text] [Related]
11. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.
Cohen SB; Cohen MD; Cush JJ; Fleischmann RM; Mease PJ; Schiff MH; Simon LS; Weaver AL
J Rheumatol Suppl; 2008 Feb; 81():4-30; quiz 31-4. PubMed ID: 19193621
[TBL] [Abstract][Full Text] [Related]
12. Abandoned therapies and unpublished trials in rheumatoid arthritis.
Keystone EC
Curr Opin Rheumatol; 2003 May; 15(3):253-8. PubMed ID: 12707578
[TBL] [Abstract][Full Text] [Related]
13. [Treatment reduction in well-controlled rheumatoid arthritis. State of knowledge].
Krüger K; Edelmann E
Z Rheumatol; 2015 Jun; 74(5):414-20. PubMed ID: 26085073
[TBL] [Abstract][Full Text] [Related]
14. Assessment and management of rheumatoid arthritis.
Haraoui B
J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
[TBL] [Abstract][Full Text] [Related]
15. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
Nagy G; van Vollenhoven RF
Arthritis Res Ther; 2015 Aug; 17(1):181. PubMed ID: 26235544
[TBL] [Abstract][Full Text] [Related]
16. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.
Pincus T; Castrejón I
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S33-40. PubMed ID: 24219039
[TBL] [Abstract][Full Text] [Related]
17. Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?
Mease P
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S59-62. PubMed ID: 24129140
[TBL] [Abstract][Full Text] [Related]
18. Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study.
Lampropoulos CE; Orfanos P; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2017; 35(2):192-200. PubMed ID: 28094760
[TBL] [Abstract][Full Text] [Related]
19. The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis.
Ruderman EM
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S29-32. PubMed ID: 24219038
[TBL] [Abstract][Full Text] [Related]
20. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
Albrecht K; Krüger K; Wollenhaupt J; Alten R; Backhaus M; Baerwald C; Bolten W; Braun J; Burkhardt H; Burmester GR; Gaubitz M; Gause A; Gromnica-Ihle E; Kellner H; Kuipers J; Krause A; Lorenz HM; Manger B; Nüßlein H; Pott HG; Rubbert-Roth A; Schneider M; Specker C; Schulze-Koops H; Tony HP; Wassenberg S; Müller-Ladner U;
Rheumatol Int; 2014 Jan; 34(1):1-9. PubMed ID: 23942828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
